{
  "version": "1.0",
  "last_updated": "2026-02-04",
  "description": "Master index of biopharma companies with classification metadata",

  "companies": [
    {
      "ticker": "KYMR",
      "name": "Kymera Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "Degrader/PROTAC",
      "therapeutic_area": "i_and_i_autoimmune",
      "therapeutic_subtype": "Dermatology",
      "thesis_type": "sum_of_parts",
      "market_cap_mm": 2100,
      "fund_ownership_pct": 4.2,
      "priority": "high",
      "has_data": true,
      "notes": "Lead degrader company; KT-621 (STAT6) in Phase 2b AD"
    },
    {
      "ticker": "ASND",
      "name": "Ascendis Pharma",
      "development_stage": "commercial_stage",
      "modality": "antibody_biologics",
      "modality_subtype": "Fc-Fusion",
      "therapeutic_area": "rare_metabolic",
      "therapeutic_subtype": "Endocrine",
      "thesis_type": "commercial_compounder",
      "market_cap_mm": 8500,
      "fund_ownership_pct": 3.1,
      "priority": "high",
      "has_data": true,
      "notes": "TransCon platform; Skytrofa approved, YORVIPATH launch"
    },
    {
      "ticker": "ARGX",
      "name": "argenx SE",
      "development_stage": "commercial_stage",
      "modality": "antibody_biologics",
      "modality_subtype": "mAb",
      "therapeutic_area": "rare_genetic",
      "therapeutic_subtype": "Neurologic",
      "thesis_type": "commercial_compounder",
      "market_cap_mm": 35000,
      "fund_ownership_pct": 2.8,
      "priority": "high",
      "has_data": false,
      "notes": "Vyvgart blockbuster; FcRn leader; multiple indications"
    },
    {
      "ticker": "NUVL",
      "name": "Nuvalent",
      "development_stage": "late_clinical",
      "modality": "small_molecule",
      "modality_subtype": "Kinase Inhibitor",
      "therapeutic_area": "oncology_precision",
      "therapeutic_subtype": "Solid Tumor",
      "thesis_type": "binary_event",
      "market_cap_mm": 6200,
      "fund_ownership_pct": 5.1,
      "priority": "high",
      "has_data": false,
      "notes": "NVL-520 (ROS1) and NVL-655 (ALK) in lung cancer"
    },
    {
      "ticker": "CNTA",
      "name": "Centessa Pharmaceuticals",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "Enzyme Inhibitor",
      "therapeutic_area": "cardiometabolic",
      "therapeutic_subtype": "CV",
      "thesis_type": "sum_of_parts",
      "market_cap_mm": 1800,
      "fund_ownership_pct": 3.5,
      "priority": "high",
      "has_data": false,
      "notes": "Lixisenatide in PH; ORX750 in narcolepsy"
    },
    {
      "ticker": "SLNO",
      "name": "Soleno Therapeutics",
      "development_stage": "late_clinical",
      "modality": "small_molecule",
      "modality_subtype": "GPCR Modulator",
      "therapeutic_area": "rare_genetic",
      "therapeutic_subtype": "Metabolic",
      "thesis_type": "ma_target",
      "market_cap_mm": 1400,
      "fund_ownership_pct": 2.2,
      "priority": "high",
      "has_data": false,
      "notes": "Diazoxide choline (DCCR) for Prader-Willi syndrome"
    },
    {
      "ticker": "EWTX",
      "name": "Edgewise Therapeutics",
      "development_stage": "mid_clinical",
      "modality": "small_molecule",
      "modality_subtype": "Enzyme Inhibitor",
      "therapeutic_area": "rare_genetic",
      "therapeutic_subtype": "Muscular",
      "thesis_type": "binary_event",
      "market_cap_mm": 2400,
      "fund_ownership_pct": 4.8,
      "priority": "high",
      "has_data": false,
      "notes": "Sevasemten (EDG-5506) for DMD; muscle-selective myosin inhibitor"
    }
  ],

  "stats": {
    "total_companies": 7,
    "with_data": 2,
    "by_priority": {
      "high": 7,
      "medium": 0,
      "low": 0
    },
    "by_stage": {
      "commercial_stage": 2,
      "late_clinical": 2,
      "mid_clinical": 3
    }
  }
}
